90 related articles for article (PubMed ID: 4039668)
1. Pharmacological interventions and myocardial infarct size in rat.
Kumar C; Singh M
Eur J Pharmacol; 1985 Feb; 109(1):117-20. PubMed ID: 4039668
[TBL] [Abstract][Full Text] [Related]
2. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
3. Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor.
Eddy LJ; Oei HH; Glenn TM
Res Commun Chem Pathol Pharmacol; 1983 Jan; 39(1):87-97. PubMed ID: 6682567
[TBL] [Abstract][Full Text] [Related]
4. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor.
Burke SE; Lefer AM; Smith GM; Smith JB
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6681711
[TBL] [Abstract][Full Text] [Related]
5. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a thromboxane synthetase inhibitor in circumflex coronary artery occlusion and reperfusion.
Huddleston CB; Lupinetti FM; Clanton J; Collins J; Oates JA; Hammon JW
Curr Surg; 1983; 40(3):211-5. PubMed ID: 6683615
[No Abstract] [Full Text] [Related]
7. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
Staiger C; Walter E; Wang NS; Schuhmacher E; de Vries J; Weber E
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):250-3. PubMed ID: 6540249
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries.
Bush LR; Campbell WB; Tilton GD; Buja LM; Willerson JT
Trans Assoc Am Physicians; 1983; 96():103-12. PubMed ID: 6687298
[No Abstract] [Full Text] [Related]
9. The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs.
Huddleston CB; Lupinetti FM; Laws KH; Collins JC; Clanton JA; Hawiger JJ; Oates JA; Hammon JW
Circ Res; 1983 May; 52(5):608-13. PubMed ID: 6682723
[No Abstract] [Full Text] [Related]
10. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Schumacher WA; Lucchesi BR
J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
Menys VC; Davies JA
Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
13. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Thaulow E; Dale J; Myhre E
Am J Cardiol; 1984 May; 53(9):1255-8. PubMed ID: 6538740
[TBL] [Abstract][Full Text] [Related]
14. Dazoxiben examined for platelet inhibitory effect in an artificial circulation.
Goldman M; Hall C; Hawker RJ; McCollum CN
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):61S-65S. PubMed ID: 6681706
[TBL] [Abstract][Full Text] [Related]
15. Reduction in myocardial neutrophil accumulation and infarct size following administration of thromboxane inhibitor U-63,557A.
Wargovich TJ; Mehta J; Nichols WW; Ward MB; Lawson D; Franzini D; Conti CR
Am Heart J; 1987 Nov; 114(5):1078-85. PubMed ID: 2960223
[TBL] [Abstract][Full Text] [Related]
16. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
17. Influence of an inhibition of thromboxane synthetase by imidazole on kidney function in rats during postnatal development.
Herceg R; Bräunlich H; Bartha J
Arch Int Pharmacodyn Ther; 1985 May; 275(1):151-9. PubMed ID: 4040739
[TBL] [Abstract][Full Text] [Related]
18. Effects of dazoxiben, an inhibitor of thromboxane synthetase, on forearm vasoconstriction in response to cold stimulation, and on human blood vessel prostacyclin production.
Cowley AJ; Jones EW; Hanley SP
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):107S-112S. PubMed ID: 6337600
[TBL] [Abstract][Full Text] [Related]
19. On the inhibitory potency of imidazole and its derivatives on thromboxane synthetase.
Tai HH; Yuan B
Biochem Biophys Res Commun; 1978 Jan; 80(1):236-42. PubMed ID: 623654
[No Abstract] [Full Text] [Related]
20. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Hock CE; Lefer AM
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
